PEAK6 Investments’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,700
Closed -$909K 5486
2022
Q3
$909K Buy
3,700
+2,900
+363% +$783K ﹤0.01% 2300
2022
Q2
$198K Sell
800
-5,800
-88% -$1.57M ﹤0.01% 4774
2022
Q1
$2.19M Buy
6,600
+2,000
+43% +$616K ﹤0.01% 1765
2021
Q4
$1.65M Sell
4,600
-15,300
-77% -$5.17M ﹤0.01% 2087
2021
Q3
$6.48M Buy
19,900
+6,500
+49% +$2.2M 0.01% 972
2021
Q2
$4.18M Buy
13,400
+2,000
+18% +$614K 0.01% 1244
2021
Q1
$3.63M Sell
11,400
-100,500
-90% -$32.2M 0.01% 1316
2020
Q4
$36.3M Sell
111,900
-7,500
-6% -$2.07M 0.08% 236
2020
Q3
$33.1M Buy
119,400
+26,900
+29% +$7.75M 0.08% 208
2020
Q2
$22.3M Buy
+92,500
New +$18.6M 0.08% 233
2020
Q1
Sell
-700
Closed -$119K 4682
2019
Q4
$119K Sell
700
-800
-53% -$148K ﹤0.01% 2795
2019
Q3
$267K Sell
1,500
-6,500
-81% -$1.41M ﹤0.01% 2721
2019
Q2
$2.08M Sell
8,000
-500
-6% -$133K 0.01% 1252
2019
Q1
$2.43M Sell
8,500
-6,400
-43% -$2.13M 0.01% 1173
2018
Q4
$4.84M Sell
14,900
-25,100
-63% -$8.72M 0.03% 660
2018
Q3
$18M Buy
+40,000
New +$15.8M 0.08% 251

Other funds holding ABMD

PEAK6 Investments's ABMD Position: Q4 2022 in Review

PEAK6 Investments sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,018 shares — an estimated $496K sold.

PEAK6 Investments first reported a position in ABMD in Q4 2018 and held it in 11 quarters. The position peaked at $8.83M in Q3 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • PEAK6 Investments reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • PEAK6 Investments sold 2,018 Abiomed Inc shares in Q4 2022, an estimated $496K.
  • PEAK6 Investments first reported a position in Abiomed Inc in Q4 2018 and held it in 11 quarters.
  • PEAK6 Investments's Abiomed Inc position peaked at $8.83M in Q3 2019.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.